Novel Drug Combinations Explored for Alcohol-Related Liver Disease and Alcohol Use

Alcohol-related Liver Disease (ALD) is a severe and progressive condition resulting from chronic heavy alcohol consumption, often co-occurring with alcohol use disorder. This disease leads to significant liver damage, including inflammation, fibrosis, and cirrhosis, with limited pharmacological options beyond abstinence. Current treatments primarily focus on managing symptoms and preventing further damage, highlighting a critical need for therapies that can simultaneously address both the underlying liver pathology and the persistent urge to drink. This Phase 2 clinical trial aims to evaluate novel pharmacological strategies to simultaneously mitigate liver damage and reduce alcohol use in individuals with ALD, addressing a major unmet medical need.